Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that it plans to begin beta testing its version 3.0 THC Breath Analyzer (“THCBA”) in southern California with an occupational health care provider located in Newport Beach. Cannabix expects to deliver its latest version of the THCBA to Alipour Medical Centre early in the new year. Alipour Medical Centre provides drug and alcohol testing services to a number of local employers in the state. The THCBA is an ideal device for employers and other markets who are seeking a way to quickly, easily and non-invasively test for recent use of ∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of marijuana that causes impairment. Cannabix will be seeking additional organizations for beta testing and welcomes interested parties to contact us via our website (cannabixtechnologies.com).

Employers everywhere are struggling with the limitations of current drug testing technology in identifying recent use of marijuana that may be causing impairment during work hours and differentiating this from recreational and medical use during nonwork hours/days.

The Cannabix device allows for more relevant THC detection from breath allowing employers to create an onsite regiment whereby they can perform pre-access testing for recent use of marijuana before and during work hours, instead of testing for drug use when employees are not at work. Cannabix will be beta testing its device in order to continue training the device’s machine learning database and improve user experience through testing feedback. The THCBA has been built to provide easy to understand screen prompts for the positive and negative detection of THC in breath in a portable manner, and can be administered without extensive training.

Current forms of testing for marijuana use can identify THC ranging from minutes to days prior to actual use, making it impossible to show the difference between the two.  Studies¹ have shown that breath is a better indicator of impairment than saliva, blood, or urine because THC is present in breath for a relatively short period of time (1-3 hours); whereas, it is excreted at detectable levels in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window. 

Dr. Nima Alipour, CEO of Alipour Medical Corp, stated, “We are very pleased to be using one of the world’s first marijuana breathalyzers in our medical facility. We know first-hand how the legalization of marijuana has affected employers in our state.  As occupational health practitioners based in Orange County, we understand the challenges that employers are facing in providing relevant drug testing for existing and new employees.  We advise corporations on how best to keep their workforce safe; identifying safety issues as they pertain to impairment, while taking into account employee rights in an environment of state legalization. Alipour Medical prides itself on deploying cutting edge technology in our practice and we look forward to helping with research, and ultimately beta testing devices alongside Cannabix Technologies in California.”

Parties interested in working with Cannabix to beta-test its Cannabix Marijuana Breathalyzer are encouraged to contact the Company at info@cannabixtechnologies.com

(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104. Himes S. et al. 2013. Cannabinoids in Exhaled Breath following Controlled Administration of Smoked Cannabis. Clinical Chemistry; 1780–1789. Beck O, Sandqvist S, Dubbelboer I, Franck J. 2011. Detection of delta9-tetrahydrocannabinol in exhaled breath collected from cannabis users. J Anal Toxicol; 35:541– 4.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing accurate, durable, portable tools to market to enable detection of marijuana-impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEOCannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.